Clal Biotechnology Industries Ltd.

About Clal Biotechnology Industries Ltd.

Clal Biotechnology Industries Ltd. (CBI) is a prominent Israeli investment firm focusing on the life sciences sector, traded on the Tel Aviv Stock Exchange under the ticker CBI. They have carved out a niche for themselves by specializing in biotechnology and medical device companies. The firm's central investment thesis revolves around identifying and nurturing companies that are developing innovative solutions for severe unmet medical needs, while also presenting considerable value and potential for investment growth. CBI's investment strategy includes a broad range of life sciences verticals such as BioTech, HealthTech and Fitness, Medical Devices and Hospital Services, Life Science, and Pharmaceuticals and Medicine. With an investment range between $3,000,000 and $55,000,000, they provide substantial backing to their portfolio companies. The CBI portfolio is diverse, including companies like Cactus Acquisition Corp. 1, which is a SPAC targeting Israeli-related entities in the healthcare sector, MediWound that focuses on severe burn and chronic wound management, and Gamida Cell, a leader in cell and immune therapy, among others. Elicio is working on technologies for agent delivery directly to antigen-presenting cells for potential applications in cancer and infectious disease treatment. Additionally, Exithera Pharmaceuticals is in the clinical stage, developing small molecule inhibitors with the potential of preventing thrombosis. Other significant holdings include Biokine Therapeutics, which is in phase III clinical development of its lead product for cancer treatment. CBI is actively involved in guiding their portfolio companies towards success, showing a commitment not just in funding but also in strategic support. They are continually updating their portfolio and seeking new opportunities in the life sciences arena to ensure they remain at the forefront of supporting transformative healthcare solutions.